Erasca announced the United States Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to ERAS-801 for the treatment of adult patients with glioblastoma with epidermal growth factor receptor gene alterations. ERAS-801 is an orally bioavailable, small molecule EGFR inhibitor that exhibited substantial central nervous system penetration in animal studies. "Receiving FTD from the FDA underscores the serious unmet medical need in patients with GBM and reinforces the promise that ERAS-801 may offer as a differentiated treatment option," said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. "GBM is an aggressive malignancy with high rates of relapse and a five-year survival rate below 10%. While over half of GBM cases are driven by EGFR alterations and/or amplifications, there are no approved EGFR inhibitors for the treatment of GBM due to the lack of sufficient brain penetration to treat primary brain tumors as well as lack of activity against EGFR alterations observed in GBM, such as EGFRvIII. To help overcome these limitations, ERAS-801 was specifically designed to have high CNS penetration and broad activity against both oncogenic and wildtype EGFR. We look forward to working closely with the FDA to expedite clinical development of ERAS-801 for these patients and anticipate reporting initial monotherapy data from the Phase 1 THUNDERBBOLT-1 trial in recurrent GBM (rGBM) in the second half of 2023."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ERAS:
- Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting
- Erasca announces publication of clinical data on naporafenib
- Erasca presents Phase 1b dose escalation data from FLAGSHIP-1 for ERAS-601
- Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting
- Erasca promotes Shannon Morris to CMO, Chandra Lovejoy to CRAO